Navigation Links
Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
Date:7/22/2013

BOULDER, Colo., July 22, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:   ARRY) will report top-line results from a placebo-controlled, randomized, double‑blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist and hold a conference call to discuss those results on Tuesday, July 23, 2013.  Ron Squarer, Chief Executive Officer, will lead the call.

(Logo:  http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)Conference Call InformationDate: Tuesday, July 23, 2013Time: 

9:00 a.m. eastern timeToll-Free: 

(888) 771-4371Toll: 

(847) 585-4405Pass Code: 

35320183Webcast, including Replay and Conference Call Slides:  http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhomeAbout Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.
Novartis began a Phase 3 trial evaluating Array-invented MEK162 in patients with NRAS-mutant melanoma in July 2013 and expects to begin a Phase 3 trial in patients with BRAF-mutant melanoma in 2013.  In addition, Array began a Phase 3 trial evaluating MEK162 in patients with low-grade serous ovarian cancer under the license agreement with Novartis in June 2013.  AstraZeneca began a pivotal trial with selumetinib (an Array-invented drug) in patients with thyroid cancer in May 2013 and expects to begin a Phase 3 trial in patients with non-small cell lung cancer during the second half of 2013.  Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche).  For more information on Array, please go to www.arraybiopharma.com.CONTACT:

Tricia Haugeto Array BioPharma Inc.(303) 386-1193thaugeto@arraybiopharma.com
'/>"/>

SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Array Instrument Market is Expected to Reach USD 3.2 Billion Globally in 2017: Transparency Market Research
2. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2013
3. Array BioPharma To Present Clinical Data On ARRY-797 At The 2012 American College Of Rheumatology Annual Meeting
4. Array BioPharma Announces Proposed Public Offering Of Common Stock
5. Array BioPharma Announces Pricing Of Public Offering Of Common Stock
6. Array BioPharma To Present At The Piper Jaffray Annual Healthcare Conference
7. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
8. Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
9. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
10. Array BioPharma To Present At The Cowen Annual Health Care Conference
11. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... -- ResMed (NYSE: RMD ), BMC (Peking, ... Winter Haven, Florida ) gaben heute bekannt, dass ... globalen Rechtsstreitigkeiten zwischen den Parteien geeinigt haben. BMC und ... im Tausch gegen Lizenzgebühren an ResMed gestattet, und ResMed ... in Florida anhängige Rechtsverfahren zwischen ...
(Date:1/23/2017)... 2017 InDex Pharmaceuticals Holding AB (publ) today ... congress of the European Crohn,s and Colitis Organisation (ECCO). The ECCO ... focus on inflammatory bowel disease (IBD). The congress is held in ... ... to again having been selected to present data at the largest ...
(Date:1/21/2017)... DUBLIN , Jan 20, 2017 ... "US Clinical Laboratory Testing Market By Type of Test (Tumor, ... Independent), & By Type of Diseases (Tuberculosis, Influenza, Cancer, HIV/AIDS ... ... an attractive destination for healthcare services, market segments, especially clinical ...
Breaking Medicine Technology:
(Date:1/22/2017)... , ... January 22, 2017 , ... Zifam Pinnacle, an ... the world, recently met with big-name retail buyers at the January ECRM Trade Show ... efficacy and uses the utmost safety standards in all of its creations to help ...
(Date:1/21/2017)... FL (PRWEB) , ... January 21, 2017 , ... Caronlab ... recently attended the January ECRM Trade Show in Hilton Head, SC, where it benefited ... reputation for the quality of its beauty and wellness products. At this trade show, ...
(Date:1/21/2017)... ... 21, 2017 , ... Seamild, the largest manufacturer of oats in China, is ... and founder. As Oat is recognized globally as one of the healthiest cereals, XieQingkui, ... believes it is a move to sow the seed of good karma. Buddhism spirit ...
(Date:1/21/2017)... ... January 21, 2017 , ... Northern California Medical Associates (NCMA) ... their multi-specialty medical group. The dermatology practice provides general dermatologic treatment, outpatient surgery, ... add this excellent dermatology practice to our group’s medical services,” explains NCMA CEO, ...
(Date:1/21/2017)... ... 21, 2017 , ... The Nobel Biocare™ dental implant company ... for its creos™ line of bone regenerative products. Specifically, the Nobel ... utilizes creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. In ...
Breaking Medicine News(10 mins):